Clinical trials: Obese Non Diabetic
Morbid Obesity
The Effects of Exenatide After Gastric Restriction
The purpose of this study is to describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide or placebo injections.
- Trial name
- AGREE (NCT00872378)
- Testing
- Exenatide
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Advanced Specialty Care
Overweight , Obesity
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07791654
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity
Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.
- Trial name
- NCT02243202
- Testing
- Canagliflozin, Phentermine
- Where
- 17 sites in United States
- Volunteers
- 335 people
- Sponsor
- Janssen Research & Development, LLC
Metabolic Syndrome, Diabetes
Lifestyle Intervention in Obese Arab Women
The study protocol aims to test the hypothesis that a lifestyle intervention program aimed to increase leisure-time physical activity and reduce body weight will improve the parameters of the metabolic syndrome and quality of…
- Trial name
- NCT00273572
- Testing
- Moderate Lifestyle Intervention, Intensive lifestyle intervention
- Where
- Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Type 2 Diabetes or Obesity Without Diabetes
Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.
Animal studies have shown that stimulation of the lingual lipid-receptor, CD 36, is accompanied by the rapid secretion of hormones in the digestive tract (incretines).
- Trial name
- NCT02028975
- Testing
- Measure the threshold of detection for linoleic acid, Oral stimulation tests, Venous blood samples
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Obesity, Weight Loss
The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
In patients initiating Semaglutide for weight management, the objective is to compare the effect of the Mediterranean diet and the high protein/low carbohydrate (HP/LC) diet CV parameters, namely arterial stiffness, measured by…
- Trial name
- NCT04990024
- Testing
- Dietary Intervention Med Diet, Dietary Intervention HP/LC Diet
- Where
- Lebanon
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- American University of Beirut Medical Center
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Insulin Sensitivity/Resistance, Semaglutide
- Trial name
- TRIM-IR (NCT06856291)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- ETH Zurich
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in…
- Trial name
- NCT00042601
- Testing
- Pramlintide acetate
- Where
- Australia
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Obesity; Endocrine, Pregnancy in Diabetic
Female Obesity Cohort and Intervention Study Group (MOCART Study Group)
This prospective observational trial includes women with high risk pregnancies complicated with hyperglycemia in pregnancy and excessive body weight.
- Conditions
- Obesity; Endocrine, Pregnancy in Diabetic, Child Obesity, Hypertension in Pregnancy
- Trial name
- MOCART (NCT04924738)
- Testing
- Monitoring and lifestyle
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Poznan University of Medical Sciences
Hypertension, Obesity
A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients
The epidemic of obesity is associated with a considerable rise in the incidence of the metabolic syndrome, type 2 diabetes mellitus, and hypertension.
- Trial name
- HOT-ACME (NCT00538486)
- Testing
- Telmisartan plus Metformin, Telmisartan, Candesartan
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Third Military Medical University
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
This study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation phase I clinical trial aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of MWN105…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07803809
- Testing
- MWN105 1, MWN105 2, MWN105 3
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obese Diabetics, Obese Non Diabetic
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
titel : Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Abstract : Background: This study that highlights the different effects of most used three GLP-RA…
- Trial name
- NCT07820111
- Testing
- Dulaglutide 1.5 MG/ML, Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician
- Where
- Saudi Arabia
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Metabolism and Nutrition Disorder, Obesity
A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers
This trial is conducted in Europe. The aim of this clinical trial is to investigate the effect of liraglutide on gastric emptying, energy expenditure and appetite, and to evaluate liraglutide pharmacokinetics in non-diabetic…
- Trial name
- NCT00978393
- Testing
- liraglutide
- Where
- Netherlands
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Non-diabetic Chronic Kidney Disease
SGLT2 Inhibitors in Glomerular Hyperfiltration
Glomerular hyperfiltration is a major risk factor for accelerated glomerular filtration rate (GFR) decline and renal and cardiovascular events despite optimized conservative therapy with blood pressure and blood glucose (in…
- Trial name
- EMPATHY (NCT04143581)
- Testing
- Empagliflozin 10 MG
- Sponsor
- Mario Negri Institute for Pharmacological Research
Obesity, Overweight
A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
This study is a randomized, double-blind, placebo-controlled, parallel phase 2 study to evaluate efficacy, safety, pharmacokinetic characteristics and immunogenicity of TG103 injection for weight management in non-diabetic…
- Trial name
- NCT06226090
- Testing
- TG103 7.5 mg, TG103 15 mg, TG103 22.5 mg
- Where
- China
- Volunteers
- 314 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
The primary objective is to demonstrate, after 52 weeks of treatment, the non-inferiority of rimonabant 20 mg once daily (od) versus glimepiride od in reducing glycosylated haemoglobin (HbA1c) in overweight/obese patients with…
- Trial name
- ALLEGRO (NCT00449605)
- Testing
- Rimonabant, Glimepiride, Metformin
- Where
- 15 sites in United States, Chile and 12 more
- Volunteers
- 508 people
- Sponsor
- Sanofi
Obesity
Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population
The primary objective of this study was to evaluate the efficacy and the safety of sibutramine vs. placebo in combination with a hypocaloric diet on weight-loss in overweight and obese Malaysian subjects.
- Trial name
- NCT00677391
- Testing
- Sibutramine
- Volunteers
- 103 people
- Sponsor
- Abbott
Insulin Resistance, Obesity
Effect of Korean Red Ginseng on Insulin Sensitivity in Non Diabetic Overweight Korean Adults
Korean red ginseng (KRG) is popular worldwide since it is believed to contain ingredients with a variety of health enhancement effects.
- Trial name
- KRGIS (NCT01616134)
- Testing
- Korea red ginseng
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The Korean Society of Ginseng
Overweight , Obesity
Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetic characteristics, efficacy, and safety of MWN105 Injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07804810
- Testing
- MWN105 1, MWN105 2, MWN105 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Metabolic Syndrome
Phospholipid and Sphingolipid Composition of High-density Lipoproteins (HDL) in Obese Non-diabetic Patients With Metabolic Syndrome
HDL in obese non-diabetic patients show major alterations in their function and thus their cardio-protective effects. These alterations could be explained by the quantitative and qualitative anomalies in the phospholipids and…
- Trial name
- SPHINGO (NCT02851602)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 89 people
- Sponsor
- Centre Hospitalier Universitaire Dijon